Studie

LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Erkrankungsgruppe:

Lymphome

Organsystem:

Lymphsystem

Stadium:

Ersterkrankung

Standort:

Bonn, Essen, Datteln, Sankt Augustin, Helios Klinikum Krefeld

EudraCT:

2017-001691-39

Prüfplan-Code:

UKM17_0023

Phase:

III

Prüfsubstanz:

Cyclophosphamide, Cytarabine, Dexamethasone, Daunorubicin, Doxorubicin, Ifosfamide, 6-Mercaptopurine, Methotrexate, PEG asparaginase, Prednisone, Prednisolone, Thioguanine, Vincristine, Vindesine

Sponsor:

Universitätsklinikum Münster